About SupplementScore

Honest, independent supplement evidence — free for everyone.

Last reviewed May 22, 2026 · Maintained by the SupplementScore Editorial Team · Published under CC-BY 4.0

SupplementScore is a free, public reference that grades dietary supplements against published clinical trials. Every score traces back to peer-reviewed research. No sponsorships, no affiliates, no ads. This page covers who we are, how scoring works, and the policies that keep the calls honest.

780+
Supplements scored
61
Trusted sources
27,000+
Studies reviewed
$0
Industry funding
On this page
How a score is built

Six clinical dimensions — each scored 1–5, with efficacy and safety weighted highest — roll into one 0–100 composite. That score, gated by the citation and safety rules below, sets the tier.

Why we exist

The right supplement can genuinely change someone's life — better sleep, less joint pain, more energy, fewer migraines. The wrong one can drain a wallet, interact with a prescription, or harm an organ. But finding honest information is nearly impossible. The supplement industry generates over $50 billion a year in the US alone, and most of what you read online is written by someone trying to sell you something.

We built SupplementScore to fix that. The long-term goal is to use the best of clinical evidence, and eventually blood work and DNA, to curate precise, personalized supplement guidance for each individual. We don't sell supplements. We don't accept sponsorships. We don't run affiliate links. SupplementScore is, and will remain, free.

Our values. Radical transparency — every score is fully traceable to its source studies. Independence first — zero industry funding, zero affiliate deals with brands we score. Living knowledge — scores evolve as the evidence evolves. Science is never settled, and neither are we.

The four evidence tiers

Every supplement on the site is placed in one of four tiers. The tier is the headline call: how confident the evidence is, and what kind of risk profile the supplement carries.

TierWhat it meansWhat moves a supplement here
Tier 1 Proven effective. Backed by multiple large RCTs and meta-analyses with consistent, replicated results across independent research groups. ≥1 systematic review or meta-analysis showing a meaningful effect, plus ≥1 independently-funded confirmatory RCT. Industry-only evidence cannot drive a Tier 1 call.
Tier 2 Promising. Supported by clinical trials, but limited to specific populations, conditions, or dosages. Real potential — awaiting larger confirmatory studies. ≥2 RCTs in a defined population with a consistent direction of effect, but small total N or no meta-analysis yet.
Tier 3 Unproven. Limited or conflicting human data. Marketing claims often outrun the research. Many popular supplements live here. Mechanistic plausibility, animal data, or single small RCTs only. Surfaced so readers can see what the evidence does and doesn't say.
Tier 4 Risky / avoid. Documented safety risks including organ damage, severe drug interactions, or death. Regulatory warnings issued. Do not use. FDA warning letter or recall, EMA / EFSA negative opinion, multiple peer-reviewed case reports of serious adverse events, or banned status in any major jurisdiction.

The six sub-scores

Each supplement carries six 1–5 sub-scores. They roll up into the headline 0–100 score shown on the card, with efficacy and safety weighted highest. The sub-scores let you see why a supplement scores the way it does, instead of treating the headline as a black box. The exact formula lives in app.js under calcScore and is open for inspection.

FieldWhat 1 meansWhat 5 means
EfficacyInsufficient evidence of benefitConclusive — meta-analytic evidence with consistent direction
SafetyDocumented serious harm at typical dosesExcellent — no adverse signals across large population studies
Research depthMinimal — <3 published trialsExtensive — >20 trials including meta-analyses
Onset8+ weeks before noticeable effectImmediate / hours
Cost / valueHigh cost for marginal benefitMeaningful effect for low cost
Drug-interaction riskSevere interactions documentedNone known

How tiers move

Tier is a function of the composite score and a citation gate. A high score alone is not enough for Tier 1; a low score alone is not enough to demote from Tier 1. A supplement only moves between tiers when both conditions for the new tier are satisfied at the same time:

Safety-driven moves are an exception: if a major regulator issues a contraindication or recall, the supplement moves to T4 within one deploy cycle regardless of efficacy score. In the prior 12 months: 12 net promotions, 4 demotions, and 1 safety-driven move. The full audit trail lives in _archive/score-changes.csv.

Worked example — psyllium husk. Sat at 70 (T2) for two years on the strength of older trials. A 2024 NIH-supported meta-analysis of 27 RCTs (PMID 38688104) lifted the efficacy score to 74. Replication was already met. Promoted T2 → T1 in April 2026.

Where the evidence comes from

Not all citations are equal. Where multiple sources speak to a single claim, the stronger evidence type carries more weight in the score. The order below is how we resolve disagreements between sources:

  1. 01Meta-analyses & Cochrane systematic reviewsPooled effect, risk-of-bias graded
  2. 02Regulator dossiersFDA / EFSA / EMA / NIH ODS / Health Canada
  3. 03Independently-funded RCTsDirect evidence in humans
  4. 04Cohort & observational studiesUseful for safety signals
  5. 05Mechanistic, animal, or anecdotalHypothesis-generating only

The primary sources every score draws from include PubMed, the Cochrane Library, ClinicalTrials.gov, NIH Office of Dietary Supplements, NCCIH, EFSA, EMA HMPC, Health Canada NNHPD, openFDA FAERS, FDA MedWatch, WHO monographs, USDA FoodData Central, DrugBank, the USPSTF, and top-tier journals (NEJM, Lancet, JAMA, BMJ, AJCN, JISSN). Critical-appraisal frameworks include GRADE, Cochrane RoB 2, AMSTAR-2, CONSORT, and PRISMA. The complete registry of 61 sources is in sources/registry.json; browse the bibliography →

All 61 sources — click any to visit
Cochrane
Systematic reviews
PubMed
NLM biomedical index
ISSN
Sports nutrition society
USPSTF
US prevention task force
EFSA
EU food safety
CDC
US public health
NIH ODS
Dietary supplements office
NCCIH
Complementary health
WHO
World Health Organization
Examine
Supplement research

What we explicitly do not use as primary sources: manufacturer literature, affiliate-driven supplement review sites, nutritional industry trade publications, celebrity-endorsed product pages, retailer product pages, multilevel-marketing materials, and influencer or podcast claims. They may appear in an article only as evidence of a marketing claim being analysed.

Funding policy

Industry-funded supplement trials report effect sizes ~20–30% larger on average than independently-funded ones, after controlling for design quality. We don't pretend this away.

Why 25% and not 0%: industry-funded trials are not worthless. Many are well-designed and add real evidence. We discount rather than discard. The number is a judgment call drawn from meta-research on funding bias; we'll revise as our own tracking accumulates.

Our own COI policy: SupplementScore is operated as a non-profit. We accept no funding from manufacturers, distributors, retailers, or affiliate programs. We do not run advertising. Hosting and tooling are paid from individual reader donations and the operator's personal funds. Editorial staff disclose any holdings (equity, consulting, speakerships) related to the supplement industry within the prior three years; anyone with active industry ties cannot author or second-read entries where the conflict applies.

Review cadence

Different content carries different stakes. We review accordingly:

ContentCadenceTriggers
Tier 4 (risky/avoid) and safety articles14 days or on regulator alertPubMed + openFDA FAERS + FDA MedWatch RSS + EFSA alerts
Tier 1 and breakthrough articles30 daysPubMed + Cochrane
Pediatric supplements30 daysPubMed + AAP + NIH ODS pediatric
Tier 2 / Tier 3 supplements60 daysPubMed + ODS / EMA
Evergreen guides and myth-busting90 daysPubMed

If FDA MedWatch or EFSA publishes an alert for a supplement we track, it jumps the queue regardless of its last-reviewed date. Every supplement card and article shows its Last reviewed date so readers can see how fresh the call is.

How interactions are modeled

The interactions system is built on three pieces. Pairs capture explicit positive synergies — vitamin D3 + K2 for bone density, iron + vitamin C for absorption — each with a 1–5 strength rating. Cautions capture explicit negative pair interactions with severity: either caution (additive risk that warrants attention) or avoid (combinations to skip). St. John's Wort + SSRIs is an avoid for serotonin syndrome; ashwagandha + thyroid medication is a caution. Mechanism groups bundle supplements that share a pathway (bleed, serotonin, sedation, stimulant, hepatotoxic, hypoglycemic, hypotensive, thyroid modulator, and others) and auto-flag any two members against each other.

When you build a stack in your profile, the system flags conflicts in three places: a chip on each card, a grouped row inside the card describing the mechanism, and a top-of-plan banner enumerating every conflict. Drug-supplement interactions are a separate parallel system, currently in build-out as Phase 2 of the roadmap.

Roadmap

Four stages toward hyper-personalized supplement recommendations.

Stage 01 · Active

Comprehensive database

780+ supplements evaluated across six clinical dimensions, every rating derived from systematic reviews, meta-analyses, and human trials across 61 trusted sources. Continuously updated.

Stage 02 · In progress

Personalized recommendations

Profile-based engine that generates a custom supplement plan from your age, sex, goals, conditions, and medications — what to take, what to avoid, dosing, timing, and interactions.

Stage 03 · Coming soon

Blood work & lab integration

Upload blood panels or urine tests to identify specific deficiencies. Results analysed against optimal ranges to recommend targeted supplements for what your body actually needs.

Stage 04 · Planned

DNA-based personalization

Incorporate MTHFR, VDR, CYP, and APOE variants to refine recommendations based on how you absorb, metabolise, and respond to specific nutrients.

What we don't claim

SupplementScore is an educational reference, not medical advice and not a medical device. We summarise evidence and provide tier calls. Individual dosing, diagnosis, and treatment decisions belong to a qualified clinician who knows your specific history.

Specifically, we do not diagnose conditions or recommend supplements as treatment for a diagnosed condition, provide individualised dosing (the doses shown are population-level ranges from clinical trials), replace pharmacist or physician review of supplement-medication interactions, endorse specific brands, or claim that any supplement prevents, treats, or cures any disease.

Scores reflect group-level clinical data; individual responses vary by genetics, diet, health status, medications, and pre-existing conditions. Supplement quality varies dramatically between brands — we do not test, certify, or endorse specific products. Always consult a qualified healthcare provider before starting, stopping, or changing supplements, especially if you are pregnant, nursing, or on medications. In a medical emergency, contact your local emergency services immediately.

Glossary

Plain-language definitions for the research terms used across the site. If you've ever wondered what "p < 0.05" means or what "GRADE" actually grades, this is for you.

Study design
RCTRandomized controlled trial
The strongest single-study design. Participants are randomly assigned to receive the intervention (e.g. a supplement) or a control (placebo or standard care). Randomization balances confounders so any difference in outcome is attributable to the intervention.
DBPCDouble-blind, placebo-controlled
An RCT where neither the participant nor the researchers measuring outcomes know who received the active compound. Eliminates placebo and observer bias. The gold standard for supplement evidence.
CrossoverCrossover trial
Each participant receives both the intervention and the control, separated by a washout period. Smaller sample size needed but only works for short-term, fully-reversible effects.
CohortCohort study
Observational. Follows a group of people over time and observes which ones develop an outcome. Can show association, not causation. Confounding (e.g. healthy-user bias) is the main weakness.
Case-controlCase-control study
Observational. Compares people with a condition to people without it, looking backward for differences. Cheap and fast but prone to recall bias.
In vitroIn vitro
Latin for "in glass". Done in cells or test tubes, not in living humans or animals. Hypothesis-generating; rarely translates directly to human effects.
Synthesizing evidence
SRSystematic review
A structured search across all published evidence on a question, using pre-specified inclusion criteria. Reduces cherry-picking. Often paired with a meta-analysis.
Meta-analysisMeta-analysis
Pools the numeric results of multiple RCTs to compute a more precise summary effect. Cochrane reviews are considered the highest-quality form. The site's Tier 1 calls usually rest on a meta-analysis with positive results.
NMANetwork meta-analysis
A meta-analysis that compares 3+ interventions even when not all of them have been directly compared head-to-head. Used to rank treatments (e.g. the 2025 Cheng NMA ranking nutraceuticals against antidepressants).
GRADEGRADE evidence rating
A standardized framework that rates the certainty of evidence as High, Moderate, Low, or Very Low based on study design, consistency, directness, precision, and publication bias.
PRISMAPRISMA reporting standard
The PRISMA checklist standardizes how systematic reviews report their methods, so you can reproduce the search and judge what was excluded.
Effect-size measures
SMDStandardized mean difference
The intervention's effect expressed in standard deviations. SMD 0.2 ≈ small, 0.5 ≈ moderate, 0.8 ≈ large. Lets you compare effect sizes across trials that used different scales.
RRRelative risk
The ratio of an event happening in the treated group vs control. RR 0.7 means 30% lower risk; RR 1.5 means 50% higher risk.
OROdds ratio
Like RR but uses odds (event:no-event) instead of probability. Approximates RR when the event is rare.
HRHazard ratio
Like RR but accounts for time-to-event. Used in survival analysis.
CIConfidence interval (95% CI)
The range within which the "true" effect probably lies. If the 95% CI for an RR crosses 1.0, the result is not statistically significant.
p-valuep-value
The probability that a result this large would happen by chance if the intervention had no real effect. p < 0.05 is the conventional cutoff for "statistically significant" — but it doesn't mean clinically meaningful.
NNTNumber needed to treat
How many people you'd need to treat to prevent one bad outcome. NNT 10 = treat 10 people for one to benefit. The lower the better.
Citation infrastructure
PMIDPubMed identifier
A unique number assigned by the U.S. National Library of Medicine to every paper indexed in PubMed. Lets you look up the exact source — every PMID on this site is a clickable link.
DOIDigital Object Identifier
A persistent ID for any published document. Resolves to the publisher's page (where the full PDF often lives behind a paywall, sometimes not).
PMCPubMed Central
The free full-text repository for biomedical research. ~6 million papers; a subset of PubMed.
COIConflict of interest
Any financial or personal relationship that could bias the research. We tag every cited paper with its disclosed COI status.
Funder typeFunder type
Who paid for the research. Categorised on this site as public (NIH, NHS, etc.), nonprofit (American Heart Association, etc.), industry (a supplement company), mixed, or none_disclosed. Tier 1 calls require at least one public/nonprofit citation.
Pharmacology terms
ULTolerable Upper Intake Level
The highest daily intake of a nutrient unlikely to cause harm in nearly all people. Set by NIH/NAS/EFSA. Above the UL, risk of toxicity rises.
RDARecommended Dietary Allowance
The intake sufficient to meet the requirement of 97–98% of healthy people. Below the RDA, deficiency risk rises.
AIAdequate Intake
Used when an RDA can't be set due to insufficient data. The AI is the average intake assumed to maintain adequacy.
EAREstimated Average Requirement
The intake that meets the requirement of 50% of healthy people in a group. Below the EAR, deficiency is statistically common.
CYP450Cytochrome P450
The liver's main drug-metabolising enzyme system. CYP3A4, CYP2D6, CYP1A2, CYP2C9, CYP2C19 are the most clinically important. Many supplements either induce (speed up) or inhibit (slow down) these — which changes prescription drug levels.
P-gpP-glycoprotein
A pump that ferries drugs out of cells. Some supplements modulate P-gp activity, which changes how much of an oral drug actually gets absorbed and how much gets cleared.
Half-lifeHalf-life
The time it takes for half of a dose to clear from the bloodstream. After 5 half-lives, ~97% is gone. Determines dosing frequency.
AUCArea Under the Curve
Total drug exposure over time. A higher AUC means more drug reached the bloodstream — relevant when evaluating bioavailability or absorption-enhancing pairings (e.g. piperine + curcumin).
CmaxCmax
Peak blood concentration after a dose.
Genetic terms
SNPSingle nucleotide polymorphism
A common one-letter difference in DNA. Some SNPs affect how you metabolise nutrients or drugs.
MTHFRMTHFR variant
The methylenetetrahydrofolate reductase gene. Common variants (C677T, A1298C) reduce conversion of folic acid to its active form. Carriers benefit from supplementing methylfolate (5-MTHF) directly.
APOE4APOE4 carrier
A variant of the apolipoprotein E gene linked to higher Alzheimer's risk. Some supplement effects (e.g. omega-3, B vitamins) differ by APOE status.
Methodology shorthand
Tier 1Tier 1 (Strong Evidence)
Composite score ≥ 72 AND at least one cited PMID with public or nonprofit funding. The "I'm comfortable taking this" tier.
Tier 2Tier 2 (Promising)
Composite score 60–71. Real evidence but limited to specific populations, doses, or outcomes.
Tier 3Tier 3 (Trending)
Popular in wellness culture but weak or inconsistent clinical evidence.
Tier 4Tier 4 (Risky / Avoid)
Documented safety risks (organ damage, drug interactions, deaths). Regulatory warnings issued.

Flag an error

If you spot an inaccurate claim, click the Flag inaccuracy button on the affected article or supplement card. The form asks for three things: the claim you think is wrong, what you think it should say, and a citation URL (PubMed, DOI, regulator dossier, or peer-reviewed paper).

The citation is required up front because it turns reader feedback into a signal we can act on. Every submission with a citation gets triaged. Submissions touching Tier 4 safety or drug interactions are escalated to same-day review — wrong information about high-stakes content is the highest-liability content on the site, and we treat it that way.

Help build the database

SupplementScore is a community effort. Clinicians, researchers, developers, and writers make the data better every day. Corrections, new evidence, or partnership all welcome.

We'll respond within 2 business days. No newsletters — just real conversations.
Latest data revisions
May 25, 2026Legacy /s/<slug>.html supplement URLs unified under the canonical /supplement.html?slug=… route — internal supplement clicks now skip the redirect hop and render directly into the canonical card. Hero search dropdown layering fixed so results no longer hide behind the filter pills.
May 25, 2026Top-100 supplement↔article evidence audit: 566 new supplement-article relationships surfaced; 85 over-tags corrected (Vitamin D3 over-tags halved, Omega-3 over-tags down 60%, Zinc-prostate caution added). Article visual template unified across 229 article pages — consistent heading hierarchy and wrapper typography site-wide.
May 22, 2026Methodology page absorbed into the About page so the editorial process and the org behind it live in one place. Article-generator dedup tightened — 38 title-level duplicate orphans removed.